Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4598315 | 0.92 | HDAC6 (0.51) | HDAC6HDAC1HDAC8HDAC3NCOR2 | |
| SCHEMBL14003044 | 0.88 | HDAC6 (0.47) | HDAC6HDAC1HDAC8HDAC3NCOR2 | |
| Hydrochloric Acid SCHEMBL4598799 | 0.87 | HDAC6 (0.46) | HDAC6HDAC1HDAC8HDAC3NCOR2 | |
| SCHEMBL27322134 | 0.81 | SLC7A5 (0.56) | HDAC8 | |
| SCHEMBL14003068 | 0.78 | OPRM1 (0.48) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL5125574 | 0.77 | HDAC8 (0.49) | HDAC6HDAC1HDAC8 | |
| SCHEMBL4598564 | 0.77 | HDAC8 (0.55) | HDAC6HDAC1HDAC8 | |
| Hydrochloric Acid SCHEMBL4596795 | 0.77 | OPRM1 (0.47) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL4758324 | 0.77 | OPRM1 (0.45) | HDAC6HDAC1HDAC8HDAC3 | |
| SCHEMBL10435928 | 0.76 | SLC7A5 (0.62) | HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200521-A1 | Novel hydroxamic acid containing amino acid derivatives | BEXEL PHARMACEUTICALS. INC. | 2008-08-21 | — | — | US | claimed |
| EP-1906731-A2 | NOVEL HYDROXAMIC ACID-CONTAINING AMINO ACID DERIVATIVES | Bexel Pharmaceuticals Inc (US) | 2008-04-09 | — | — | EP | claimed |
| WO-2007005603-A2 | NOVEL HYDROXAMIC ACID-CONTAINING AMINO ACID DERIVATIVES | BEXEL PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | WO | claimed |
| US-20070004776-A1 | Novel hydroxamic acid-containing amino acid derivatives | BEXEL PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200521-A1 | Novel hydroxamic acid containing amino acid derivatives | HGFAC, HCAR2, BCAT1 | HDAC6 639/4885HDAC1 161/4885HDAC8 154/4885 |
| US-20070004776-A1 | Novel hydroxamic acid-containing amino acid derivatives | HGFAC, HCAR2, BCAT1 | HDAC6 684/4885HDAC1 163/4885HDAC8 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.